Literature DB >> 11139252

Exon skipping in the ATM gene in normal individuals: the effect of blood sample storage on RT-PCR analysis.

G W Birrell1, J R Ramsay, J J Tung, M F Lavin.   

Abstract

Mutations in ATM, the gene defective in the human genetic disorder ataxia-telangiectasia (A-T), have been described in A-T patients and in a variety of tumor samples. Most of these arise due to exon skipping. We developed an RT-PCR based protein truncation test (PTT) to screen for ATM mutations in breast cancer patients showing adverse response to radiotherapy. An additional PTT product was evident in the ATM gene in peripheral blood mononuclear cells (PBMCs) from blood samples that were collected 2 days or more prior to RNA extraction. Lymphoblastoid cell lines established from the same blood samples showed no evidence of the additional band. Cloning and sequencing of the additional RT-PCR product revealed an exact deletion of exon 20 (2639 del 200), pointing to exon skipping. RT-PCR analysis of RNA extracted from freshly prepared PBMCs from 3 normal individuals showed no evidence of the additional RT-PCR product but when the blood was stored for 2-3 days prior to RNA extraction the lower molecular weight band was evident in every sample. DNA sequencing confirmed this to be due to loss of exon 20. These data suggest that mRNA-based mutation analysis on ATM should be carried out on unstored blood samples to avoid artificial loss of exons that give rise to apparent mutations. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11139252     DOI: 10.1002/1098-1004(2001)17:1<75::AID-HUMU16>3.0.CO;2-6

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  4 in total

Review 1.  Biobanking in genomic medicine.

Authors:  Jane H Zhou; Aysegul A Sahin; Jeffrey N Myers
Journal:  Arch Pathol Lab Med       Date:  2015-06       Impact factor: 5.534

2.  Sample processing obscures cancer-specific alterations in leukemic transcriptomes.

Authors:  Heidi Dvinge; Rhonda E Ries; Janine O Ilagan; Derek L Stirewalt; Soheil Meshinchi; Robert K Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

3.  Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia.

Authors:  Math P Cuajungco; Maire Leyne; James Mull; Sandra P Gill; Weining Lu; David Zagzag; Felicia B Axelrod; Channa Maayan; James F Gusella; Susan A Slaugenhaupt
Journal:  Am J Hum Genet       Date:  2003-02-06       Impact factor: 11.025

4.  Tocotrienol Treatment in Familial Dysautonomia: Open-Label Pilot Study.

Authors:  David Cheishvili; Channa Maayan; Naama Holzer; Jeanna Tsenter; Elad Lax; Sophie Petropoulos; Aharon Razin
Journal:  J Mol Neurosci       Date:  2016-04-30       Impact factor: 3.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.